Biotech Values

[drbio45]

In the trial that pfizer did against Humira, Humira had a 39 percent acr20 response

In this trial Humira's acr20 reponse was 59 percent they highest it ever reached in a clinical trial, so there was something else that was going on

The way azn and rigel are positioning the drug is that it has the best response in protecting bone loss in RA. That is a meaningful endpoint and if it succeeds that would be a meaningful claim in the market place